Print

FDA Panel Mixed on King Pharmaceuticals┬«, Inc., Pain Therapeutics (PTIE) Drug; FDA Scheduled to Act By December 10 Under Six-Month Priority Review  
11/14/2008 7:16:12 AM

Nov. 13 (Bloomberg) -- Pain Therapeutics Inc. and King Pharmaceuticals Inc.'s experimental pain pill Remoxy is less susceptible to abuse than Purdue Pharma LP's OxyContin, members of a U.S. panel said, suggesting the drug will win approval.
//-->